将初诊为T2DM的60例病人随机应用诺和锐30和格列美脲治疗12周,结果:两组的FPG和2hPG、HOMA-IR均明显下降(P<0.05);诺和锐30组HbA1c下降更明显(P<0.01),两组HOMA-β较治疗前明显升高(P<0.05),但两组间无差异;均无不良事件发生,结论:T2DM初期使用诺和锐30比格列美脲更有效的控制血糖、恢复胰岛β细胞功能和改善胰岛素抵抗。 60 patients newly diagnosed with T2DM were treated with Novo-Rui-Ru 30 and glimepiride for 12 weeks. Results: FPG, 2hPG and HOMA-IR of both groups were significantly decreased (P <0.05) (P <0.01). HOMA-β in both groups was significantly higher than that before treatment (P <0.05), but there was no difference between the two groups. No adverse events occurred. Conclusion: Lemonide more effective in controlling blood sugar, restore islet β-cell function and improve insulin resistance.